VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
VYNE on Nasdaq
Shares outstanding
18,514,484
Price per share
$0.58
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
3,924,005
Total reported value
$1,315,944
% of total 13F portfolios
0%
Share change
-4,124,763
Value change
-$9,032,746
Number of holders
31
Price from insider filings
$0.58
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CITADEL ADVISORS LLC 0% -103% $1,250 -$367,360 3,732 -100% Kenneth Griffin 30 Sep 2025

As of 30 Sep 2025, 31 institutional investors reported holding 3,924,005 shares of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE). This represents 21% of the company’s total 18,514,484 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) together control 21% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 4.6% 851,353 0% $285,203
ACORN CAPITAL ADVISORS, LLC 3.2% 586,572 -20% 0.1% $199,434
Shay Capital LLC 2.7% 492,577 0.03% $165,013
ACADIAN ASSET MANAGEMENT LLC 2.4% 446,414 +1891% 0% $148,000
Ikarian Capital, LLC 1.6% 290,000 0% 0.02% $97,149
TWO SIGMA INVESTMENTS, LP 1.2% 220,788 0% $73,964
VANGUARD GROUP INC 1% 190,383 -62% 0% $63,778
JANE STREET GROUP, LLC 0.79% 147,120 +18% 0% $49,285
GEODE CAPITAL MANAGEMENT, LLC 0.74% 137,122 +2.8% 0% $45,938
BOOTHBAY FUND MANAGEMENT, LLC 0.58% 106,459 0% 0% $35,664
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.42% 76,958 0% 0% $25,781
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.31% 57,763 -0.09% 0% $19,351
TWO SIGMA ADVISERS, LP 0.31% 56,600 0% $18,961
Rangeley Capital, LLC 0.27% 50,000 0.02% $16,750
CORSAIR CAPITAL MANAGEMENT, L.P. 0.27% 50,000 +400% 0% $16,750
BlackRock, Inc. 0.24% 44,404 -0% 0% $14,875
GSA CAPITAL PARTNERS LLP 0.19% 35,921 +167% 0% $12,000
NORTHERN TRUST CORP 0.12% 23,110 0% 0% $7,742
COMMONWEALTH EQUITY SERVICES, LLC 0.1% 18,298 0% 0% $6,000
STATE STREET CORP 0.09% 15,765 0% 0% $5,281
Harvest Investment Services, LLC 0.06% 11,059 -78% 0% $3,705
UBS Group AG 0.03% 5,572 0% $1,866
Tower Research Capital LLC (TRC) 0.02% 3,597 +28% 0% $1,205
ROYAL BANK OF CANADA 0.01% 2,440 0% 0% $1,000
BANK OF AMERICA CORP /DE/ 0.01% 1,532 +4.3% 0% $513

Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 26,051 $14,610 +$14,000 $0.58 3
2025 Q3 3,924,005 $1,315,944 -$9,032,746 $0.34 31
2025 Q2 8,048,768 $13,279,291 +$1,503,898 $1.65 44
2025 Q1 7,109,939 $11,401,092 -$2,382,241 $1.58 36
2024 Q4 7,028,274 $23,320,995 +$606,162 $3.35 34
2024 Q3 7,312,555 $14,256,902 -$1,226,342 $1.88 31
2024 Q2 7,942,286 $16,030,293 +$243,077 $1.97 30
2024 Q1 6,405,086 $19,663,149 +$378,435 $3.07 29
2023 Q4 7,863,834 $18,322,345 +$17,207,859 $2.33 32
2023 Q3 360,099 $1,445,870 -$33,734 $4.04 20
2023 Q2 375,960 $1,532,386 +$198,131 $4.10 19
2023 Q1 335,259 $1,031,948 +$1,031,948 $3.08 19